Maite Bourlon, Urology Oncologist at the National Institute of Medical Sciences and Nutrition Salvador Zubirán, shared on Twitter:
“Bristol Myers Squib Press release on CheckMate-67T study of subcutaneous Nivolumab while The European Society for Medical Oncology (ESMO) begins
- P3 trial of SC Nivo vs IV Nivo
- Meets co-primary endpoints of Pharmacokinetics
- Meets non-inferiority in ORR (secondary endpoint)
Great team Laurence Albiges, Comprehensive Care Clinic for Genito-Urinary Tumors.”
Source: Maite Bourlon/Twitter